🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalEU EMA compounding guidance — 2026 regulatory update

EU EMA compounding guidance — 2026 regulatory update

amsterdam_pete Mon, Jun 8, 2026 at 2:21 AM 9 replies 198 viewsPage 1 of 2
amsterdam_pete
Senior Member
1,567
6,789
Feb 2024
Netherlands
Jun 8, 2026 at 2:21 AM#1

Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about compounded supply, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

The condition it depends on

Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.

The practical version

Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

What I am not sure about

So the question, as narrowly as I can put it: why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission. Practical detail welcome, however dull — the duller the better.

— amsterdam_pete · corrections welcome and will be edited into this post with credit
36 6JakeSmashed95, NauseaFreeNow, SteveThurs and 33 others
Reply Quote Save Share Report
julia.endo
Senior Member
1,890
9,012
Feb 2024
Cincinnati, OH
Jun 8, 2026 at 2:41 AM#2
amsterdam_pete said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Agreeing with amsterdam_pete, and the qualification matters more than the agreement. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

Last edited: Jun 8, 2026 at 8:41 AM
35 5mark_tokyo, hans_munich, jason_sac26 and 32 others
Reply Quote Save Share Report
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Jun 8, 2026 at 3:01 AM#3
amsterdam_pete said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

34 4Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 31 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
LipidDoc_ATL
Senior Member
1,123
5,678
Apr 2024
Atlanta, GA
Jun 8, 2026 at 3:21 AM#4

Answering the narrow version, because the broad one does not have a single answer. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

Last edited: Jun 8, 2026 at 8:21 AM
33 3DebRD_ATL, KristenIndy, MarkLI_maint and 30 others
Reply Quote Save Share Report
quinn_sf
Member
489
2,123
Jun 2024
San Francisco, CA
Jun 8, 2026 at 5:17 AM#5
julia.endo said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Same experience, arrived at from the opposite direction. I had assumed I was the exception until I read this.

32 2Dr.EndoEP, GraceAZ_72, carl_compliance and 29 others
Reply Quote Save Share Report

Similar Threads

UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
UK Boots Wegovy availability — patient experience thread17 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register